Last checked at 22 Dec 2017 09:24
Creo Medical Group plc
Director/PDMR Dealing
The Company announces that on 22 December 2017, Christopher Hancock, Chief Technology Officer, transferred ordinary shares from his personal holding to his self-invested personal pension (SIPP) via the sale of 36,716 ordinary shares at a price of 69.5p per share and the purchase of 36,664 ordinary shares at a price of 69.5p per share. Following these transactions, Mr Hancock's total interest in ordinary shares is 4,880,098 ordinary shares.
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||
a)
| Name
| Chris Hancock | ||||||
2
| Reason for the notification
| |||||||
a)
| Position/status
| Chief Technology Officer | ||||||
b)
| Initial notification /Amendment
| Initial | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a)
| Name
| Creo Medical Group plc | ||||||
b)
| LEI
| 213800H188ZDCWWXFA21 | ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of £0.001 each
GB00BZ1BLL44 | ||||||
b)
| Nature of the transaction
| Transfer of ordinary shares to SIPP via sale and purchase | ||||||
c)
| Price(s) and volume(s)
|
| ||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
Weighted average price of 69.5 pence per share
| ||||||
e)
| Date of the transaction
| 21 December 2017 | ||||||
f)
| Place of the transaction
| London Stock Exchange | ||||||
Contacts
Creo Medical: | Cenkos: | FTI Consulting: |
Richard Rees +44 (0)129 160 6005 Richard.Rees@creomedical.com | Camilla Hume/Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) +44 (0)207 397 8900 | Brett Pollard / Mo Noonan +44 (0)203 727 1000 creo@fticonsulting.com |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, www.creomedical.com.